Takeda Pharmaceutical Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Takeda Pharmaceutical kazanç ve gelirin sırasıyla yıllık 11.8% ve 0.8% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 11.8% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 4.1% olacağı tahmin edilmektedir.

Anahtar bilgiler

11.8%

Kazanç büyüme oranı

11.8%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	11.8%
Gelir büyüme oranı	0.8%
Gelecekteki özkaynak getirisi	4.1%
Analist kapsamı	Good
Son güncelleme	05 Nov 2024

Gelecekteki son büyüme güncellemeleri

Results: Takeda Pharmaceutical Company Limited Exceeded Expectations And The Consensus Has Updated Its Estimates

Nov 04

Earnings Beat: Takeda Pharmaceutical Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Aug 02

Takeda Pharmaceutical Company Limited (TSE:4502) Yearly Results: Here's What Analysts Are Forecasting For This Year

Jun 30

Recent updates

Results: Takeda Pharmaceutical Company Limited Exceeded Expectations And The Consensus Has Updated Its Estimates

Nov 04

Takeda Pharmaceutical (TSE:4502) Is Increasing Its Dividend To ¥98.00

Sep 24

Why Investors Shouldn't Be Surprised By Takeda Pharmaceutical Company Limited's (TSE:4502) P/E

Sep 20

Takeda Pharmaceutical's (TSE:4502) Upcoming Dividend Will Be Larger Than Last Year's

Aug 08

Earnings Beat: Takeda Pharmaceutical Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Aug 02

Takeda Pharmaceutical (TSE:4502) Is Increasing Its Dividend To ¥98.00

Jul 25

Takeda Pharmaceutical's (TSE:4502) Upcoming Dividend Will Be Larger Than Last Year's

Jul 11

Takeda Pharmaceutical Company Limited (TSE:4502) Yearly Results: Here's What Analysts Are Forecasting For This Year

Jun 30

Takeda Pharmaceutical (TSE:4502) Takes On Some Risk With Its Use Of Debt

Jun 11

Some Investors May Be Willing To Look Past Takeda Pharmaceutical's (TSE:4502) Soft Earnings

May 21

Takeda Pharmaceutical Company Limited Just Recorded A 6.0% EPS Beat: Here's What Analysts Are Forecasting Next

May 12

Kazanç ve Gelir Büyüme Tahminleri

TSE:4502 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (JPY Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
3/31/2027	4,530,480	292,370	686,503	973,123	17
3/31/2026	4,461,038	229,800	695,167	950,866	18
3/31/2025	4,458,730	114,395	377,184	879,592	14
9/30/2024	4,546,083	289,996	536,390	876,306	N/A
6/30/2024	4,413,134	149,920	444,957	794,248	N/A
3/31/2024	4,263,762	144,067	235,614	716,344	N/A
12/31/2023	4,169,049	178,219	-129,035	731,449	N/A
9/30/2023	4,154,414	191,626	129,243	963,227	N/A
6/30/2023	4,113,631	301,398	180,765	985,315	N/A
3/31/2023	4,027,478	317,017	343,467	977,156	N/A
12/31/2022	3,944,611	274,525	817,615	1,059,047	N/A
9/30/2022	3,749,354	213,167	789,089	1,028,328	N/A
6/30/2022	3,591,868	197,389	798,367	1,040,488	N/A
3/31/2022	3,569,006	230,059	937,068	1,123,105	N/A
12/31/2021	3,465,991	438,515	902,309	1,148,481	N/A
9/30/2021	3,401,450	473,105	777,572	1,018,931	N/A
6/30/2021	3,345,565	431,178	793,645	1,031,928	N/A
3/31/2021	3,197,812	376,005	774,463	1,010,931	N/A
12/31/2020	3,199,240	180,631	608,015	795,408	N/A
9/30/2020	3,221,804	56,051	498,511	720,676	N/A
6/30/2020	3,243,917	119,743	479,618	694,824	N/A
3/31/2020	3,291,188	44,241	452,042	669,752	N/A
12/31/2019	3,236,697	13,275	402,421	601,798	N/A
9/30/2019	2,876,782	83,262	399,600	551,732	N/A
6/30/2019	2,496,511	63,959	266,965	408,797	N/A
3/31/2019	2,097,224	135,192	194,365	328,479	N/A
12/31/2018	1,780,976	110,414	221,992	336,742	N/A
9/30/2018	1,769,726	140,738	225,190	328,658	N/A
6/30/2018	1,772,125	120,339	N/A	343,761	N/A
3/31/2018	1,770,531	186,886	N/A	377,854	N/A
12/31/2017	1,785,773	190,172	N/A	376,566	N/A
9/30/2017	1,762,667	163,457	N/A	316,619	N/A
6/30/2017	1,746,286	160,202	N/A	285,157	N/A
3/31/2017	1,732,051	114,940	N/A	261,363	N/A
12/31/2016	1,729,967	132,194	N/A	-8,176	N/A
9/30/2016	1,754,130	150,081	N/A	42,293	N/A
6/30/2016	1,795,088	155,110	N/A	57,618	N/A
3/31/2016	1,807,378	80,166	N/A	25,491	N/A
12/31/2015	1,831,096	-111,874	N/A	203,553	N/A
9/30/2015	1,830,521	-152,827	N/A	192,836	N/A
6/30/2015	1,812,971	-154,591	N/A	189,123	N/A
3/31/2015	1,777,824	-145,775	N/A	182,517	N/A
12/31/2014	1,744,795	75,405	N/A	N/A	N/A
9/30/2014	1,714,694	103,390	N/A	240,094	N/A
6/30/2014	1,692,531	110,981	N/A	N/A	N/A
3/31/2014	1,691,685	106,658	N/A	148,335	N/A
12/31/2013	1,655,033	103,330	N/A	N/A	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 4502 'nin tahmini kazanç büyümesi (yıllık 11.8% ) tasarruf oranının ( 0.3% ) üzerindedir.

Kazançlar ve Piyasa: 4502 şirketinin kazançlarının (yıllık 11.8% ) JP pazarından (yıllık 8.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: 4502 şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: 4502 şirketinin gelirinin (yıllık 0.8% ) JP pazarından (yıllık 4.2% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 4502 şirketinin gelirinin (yıllık 0.8% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 4502 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 4.1 %).

Takeda Pharmaceutical Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Results: Takeda Pharmaceutical Company Limited Exceeded Expectations And The Consensus Has Updated Its Estimates

Takeda Pharmaceutical Company Limited Raises Earnings Guidance for the Full Year 2024

Consensus EPS estimates increase by 13%

Earnings Beat: Takeda Pharmaceutical Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Consensus EPS estimates fall by 17%

Takeda Pharmaceutical Company Limited (TSE:4502) Yearly Results: Here's What Analysts Are Forecasting For This Year

Recent updates

Results: Takeda Pharmaceutical Company Limited Exceeded Expectations And The Consensus Has Updated Its Estimates

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Takeda Pharmaceutical Company Limited Raises Earnings Guidance for the Full Year 2024

Takeda Receives Approval from the Japanese Ministry of Health, Labour and Welfare to Manufacture and Market Fruquintinib for Previously Treated Colorectal Cancer

Takeda Pharmaceutical (TSE:4502) Is Increasing Its Dividend To ¥98.00

Why Investors Shouldn't Be Surprised By Takeda Pharmaceutical Company Limited's (TSE:4502) P/E

Upcoming dividend of JP¥98.00 per share

Consensus EPS estimates increase by 13%

Takeda Pharmaceutical's (TSE:4502) Upcoming Dividend Will Be Larger Than Last Year's

Takeda Receives European Commission Approval for ADZYNMA®

Earnings Beat: Takeda Pharmaceutical Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Takeda Pharmaceutical (TSE:4502) Is Increasing Its Dividend To ¥98.00

Consensus EPS estimates fall by 17%

Takeda Pharmaceutical's (TSE:4502) Upcoming Dividend Will Be Larger Than Last Year's

Final dividend of JP¥98.00 announced

Corza Medical Inc. completed the acquisition of TachoSil manufacturing operations in Linz, Austria. from Takeda Pharmaceutical Company Limited (TSE:4502).

Takeda Pharmaceutical Company Limited (TSE:4502) Yearly Results: Here's What Analysts Are Forecasting For This Year

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Takeda Receives European Commission Approval for FRUZAQLA® (fruquintinib)

Takeda Receives Approval from European Commission for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

Consensus EPS estimates fall by 18%

Takeda Announces Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting

Takeda Announces Phase 3 Topline Results for Soticlestat in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome

Takeda Pharmaceutical (TSE:4502) Takes On Some Risk With Its Use Of Debt

Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Consensus EPS estimates fall by 11%

Some Investors May Be Willing To Look Past Takeda Pharmaceutical's (TSE:4502) Soft Earnings

Takeda Pharmaceutical Company Limited Just Recorded A 6.0% EPS Beat: Here's What Analysts Are Forecasting Next

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Takeda Pharmaceutical Company Limited Announces Demise of its Board Member, Olivier Bohuon

Takeda Receives Positive Chmp Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

U.S. Food and Drug Administration Approves Subcutaneous Administration of Takeda Pharmaceutical Company Limited's ENTYVIO (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease

Alinamin Pharmaceutical Co., Ltd. acquired Nihon Pharmaceutical Co., Ltd. from Takeda Pharmaceutical Company Limited (TSE:4502).

Takeda Pharmaceutical (TSE:4502) Is Due To Pay A Dividend Of ¥94.00

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2024

Takeda Pharmaceuticals U.S.A, Inc. Announces Approval of Adzynma Intravenous Injection 1500 (Apadamtase Alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura

Upcoming dividend of JP¥94.00 per share

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL

Takeda Pharmaceutical (TSE:4502) Has Announced A Dividend Of ¥94.00

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (Tak-079), A Potential Best-In-Class Anti-Cd38 Monoclonal Antibody, for Primary Immune Thrombocytopenia

Takeda Pharmaceutical (TSE:4502) Will Pay A Dividend Of ¥94.00

FDA Approves Takeda's EOHILIA (budesonide Oral Suspension)

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024

Takeda Pharmaceutical Company Limited Reaffirms Earnings Guidance for the Full Year of Fiscal 2024

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Takeda Pharmaceutical Company Limited Announces Chief Financial Officer Succession, Effective April 1, 2024

Takeda's Gammard Liquidid®? Approves by U.S. Fda for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

Takeda Announces U.S. Food and Drug Administration Approves Hyqvia® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]

Takeda Pharmaceutical Company Limited to Report Q2, 2025 Results on Oct 31, 2024

Takeda Receives Positive Chmp Opinion for Hyqvia as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

Consensus EPS estimates increase by 13%

Consensus EPS estimates fall by 24%

The European Commission Approves Label Update for Takhzyro®? (Lanadelumab), Expanding Its Use to A Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (Hae)

U.S. Fda Approves Takeda's Adzynma (Adamts13, Recombinant-Krhn) as the First and Only Recombinant Adamts13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombotic Thrombocytopenic Purpura

Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

Takeda Pharmaceutical Company Limited Announces Late-Breaking Data from Phase 2B Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis At American College of Rheumatology Convergence Annual Meeting

Takeda Pharmaceutical Company Limited Revises Earnings Guidance for the Fiscal Year Ending March 31, 2024

Takeda Pharmaceutical Company Limited Announces Dividend for the Second Quarter Ended September 30, 2023, Payable on December 1, 2023 and Provides Year-End Dividend Guidance for the Year Ending March 31, 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Takeda Pharmaceutical Company Limited Announces European Commission Approves ADCETRIS (Brentuximab Vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD

Takeda Pharmaceutical Company Limited Announces Phase 3 ADMIRE-CD II Study

Takeda Pharmaceutical Company Limited to Report Q3, 2024 Results on Feb 01, 2024

Takeda Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

Takeda Pharmaceutical Company Limited Announces U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

Takeda Announces Approval of CUVITRU Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema in Patients Aged 2 Years and Older

Takeda Announces FDA Acceptance of NDA Resubmission of Tak-721 (Budesonide Oral Suspension) for the Short-Term Treatment of Eosinophilic Esophagitis

Upcoming dividend of JP¥94.00 per share at 4.0% yield